Dynavax Technologies Corp (NAS:DVAX)
$ 13 -0.03 (-0.23%) Market Cap: 1.71 Bil Enterprise Value: 1.17 Bil PE Ratio: 100.23 PB Ratio: 2.51 GF Score: 70/100

Dynavax Technologies Corp at JPMorgan Healthcare Conference Transcript

Jan 11, 2024 / 07:15PM GMT
Release Date Price: $13.89 (+0.58%)
Unidentified_Participant

Hi, everyone, welcome. In terms of logistics, we're going to run through the presentation and then open it up for Q&A without much further ado, pleasue to present Dynamax.

Ryan Spencer Dynavax Technologies Corporation;CEO

Thank you, Luca, and thank you for JPMorgan for allowing us to present today. I'm Ryan Spencer, the CEO of Dynavax. And before I begin, I'll remind you all that we're going to make some forward-looking statements today that contain some risks and uncertainties that are detailed in our Forms 10-Q and 10-K filings, which I encourage you all to read.

Just to start off a little bit about Dynavax and who we are. We are a vaccine company focused on developing novel vaccines that help protect the world against infectious disease. We've had pretty good advancement in our core business over the last few years, which I will walk us through here.

First, our pipeline, our portfolio of assets are basically built on the backbone of our core technology, which is TLR biology, utilizing TLR9 to over the course of

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot